Antonio Rispo

Dr. Antonio Rispo

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
RTR. Tortora
R. Tortora
PCP. Capone
P. Capone
GSG. De Stefano
G. De Stefano
NIN. Imperatore
N. Imperatore
NGN. Gerbino
N. Gerbino
ARAntonio Rispo
Antonio Rispo

1 April 2013 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
FCFabiana Castiglione
Fabiana Castiglione
PMPier Paolo Mainenti
Pier Paolo Mainenti
GPGiovanni Domenico De Palma
Giovanni Domenico De Palma
ATAnna Testa
Anna Testa
LBLuigi Bucci
Luigi Bucci
ARAntonio Rispo
Antonio Rispo
Background. The diagnosis of small bowel Crohn’s disease (CD) is performed by ileocolonoscopy, whereas the assessment of its extension can be achieved by radiol

20 November 2003 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
FCFabiana Castiglione
Fabiana Castiglione
ARAntonio Rispo
Antonio Rispo
EGE. Di Girolamo
E. Di Girolamo
ACA. Cozzolino
A. Cozzolino
FMF. Manguso
F. Manguso
GMG. Mazzacca
G. Mazzacca
Summary: Background : Small bowel bacterial overgrowth is common in Crohn's disease but its treatment is not clearly defined. Metronidazole and ciprofloxacin are effective antibiotics in active Crohn's disease.Aim : To investigate the efficacy of metronidazole and ciprofloxacin in the treatment of bacterial overgrowth in patients with Crohn's disease.Patients and methods : We performed the lactulose breath test in 145 consecutive patients affected by Crohn's disease. Patients positive to the lactulose breath test underwent a glucose breath test to confirm the overgrowth. These patients were randomized in two treatment groups: metronidazole 250 mg t.d.s. (Group A) and ciprofloxacin 500 mg b.d. (Group B), both orally for 10 days. The glucose breath test was repeated at the end of treatment. The clinical outcome after therapy was also recorded.Results : Bacterial overgrowth was present in 29 patients (20%). Breath test normalization occurred in 13 out of 15 patients treated by metronidazole and in all 14 patients treated by ciprofloxacin (P = ns). In both groups antibiotic treatment induced an improvement of intestinal symptoms: bloating (Group A 85% and Group B 83%), stool softness (44% and 50%), and abdominal pain (50% and 43%).Conclusions : Small bowel bacterial overgrowth is a frequent condition in Crohn's disease which can be effectively treated by metronidazole or ciprofloxacin.

1 May 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
FCFabiana Castiglione
Fabiana Castiglione
PMPier Paolo Mainenti
Pier Paolo Mainenti
ATAnna Testa
Anna Testa
NINicola Imperatore
Nicola Imperatore
GPGiovanni Domenico De Palma
Giovanni Domenico De Palma
ARAntonio Rispo
Antonio Rispo

1 November 2005 in Gastroenterology
Verified
Journal Article
Closed access
LMLuigi Maiuri
Luigi Maiuri
Carolina CiacciCarolina Ciacci
Carolina Ciacci
IRIda Ricciardelli
Ida Ricciardelli
LVLoredana Vacca
Loredana Vacca
VRValeria Raia
Valeria Raia
MLMarco Londei
Marco Londei

1 September 2008 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
FCFabiana Castiglione
Fabiana Castiglione
LBLuigi Bucci
Luigi Bucci
GPGiuseppe Pesce
Giuseppe Pesce
GPGiovanni Domenico De Palma
Giovanni Domenico De Palma
LCLuigi Camera
Luigi Camera
ARAntonio Rispo
Antonio Rispo
Background. Postsurgical recurrence (PSR) is very common in patients with Crohn's disease (CD) and previous surgery. Endoscopy is crucial for the diagnosis of P